Standard BioTools Inc. Sales Revenue, Goods, Net (Deprecated 2018-01-31)
Standard BioTools Inc. (LAB) reported Sales Revenue, Goods, Net (Deprecated 2018-01-31) of $21.78 million for the 3-month period ending 2018-06-30, per its 10-Q filed 2018-08-08.
Discontinued › Expense Statement › Operating Expenses
us-gaap:SalesRevenueGoodsNet · last filed 2018-08-08
- Standard BioTools Inc. sales revenue, goods, net (deprecated 2018-01-31) for the quarter ending 2018-06-30 was $21.78M, a 11.68% increase year-over-year.
- Standard BioTools Inc. sales revenue, goods, net (deprecated 2018-01-31) for the quarter ending 2018-03-31 was $20.48M, a 3.90% decline year-over-year.
- Standard BioTools Inc. sales revenue, goods, net (deprecated 2018-01-31) for the quarter ending 2017-12-31 was $40.55M, a 11.56% increase year-over-year.
- Standard BioTools Inc. sales revenue, goods, net (deprecated 2018-01-31) for the quarter ending 2017-09-30 was $20.58M, a 14.36% increase year-over-year.
- Standard BioTools Inc. sales revenue, goods, net (deprecated 2018-01-31) for fiscal 2017 was $101.94M, a 2.40% decline from fiscal 2016.
- Standard BioTools Inc. sales revenue, goods, net (deprecated 2018-01-31) for fiscal 2016 was $104.45M, a 8.95% decline from fiscal 2015.
- Standard BioTools Inc. sales revenue, goods, net (deprecated 2018-01-31) for fiscal 2015 was $114.71M, a 1.50% decline from fiscal 2014.
- Standard BioTools Inc. sales revenue, goods, net (deprecated 2018-01-31) for fiscal 2014 was $116.46M, a 65.90% increase from fiscal 2013.
| Period end | Sales Revenue, Goods, Net (Deprecated 2018-01-31) 3 month | Sales Revenue, Goods, Net (Deprecated 2018-01-31) 3 month as first filed | Sales Revenue, Goods, Net (Deprecated 2018-01-31) 6 month | Sales Revenue, Goods, Net (Deprecated 2018-01-31) 6 month as first filed | Sales Revenue, Goods, Net (Deprecated 2018-01-31) 9 month | Sales Revenue, Goods, Net (Deprecated 2018-01-31) 9 month as first filed | Sales Revenue, Goods, Net (Deprecated 2018-01-31) 12 month | Sales Revenue, Goods, Net (Deprecated 2018-01-31) 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2018-06-30 | $21.78M 10-Q · filed 2018-08-08 | $42.25M 10-Q · filed 2018-08-08 | $82.81M derived: sum of 3 quarters · filed 2018-08-08 | $103.38M derived: sum of 4 quarters · filed 2018-08-08 | ||||
| 2018-03-31 | $20.48M 10-Q · filed 2018-05-08 | $61.03M derived: sum of 2 quarters · filed 2018-05-08 | $81.61M derived: sum of 3 quarters · filed 2018-05-08 | $101.11M derived: sum of 4 quarters · filed 2018-08-08 | ||||
| 2017-12-31 | $40.55M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-08 | $61.13M derived: sum of 2 quarters · filed 2018-03-08 | $80.63M derived: sum of 3 quarters · filed 2018-08-08 | $101.94M 10-K · filed 2018-03-08 | ||||
| 2017-09-30 | $20.58M 10-Q · filed 2017-11-07 | $40.08M derived: sum of 2 quarters · filed 2018-08-08 | $61.38M 10-Q · filed 2017-11-07 | $97.73M derived: sum of 4 quarters · filed 2018-08-08 | ||||
| 2017-06-30 | $19.50M 10-Q · filed 2018-08-08 | $40.81M 10-Q · filed 2018-08-08 | $77.16M derived: sum of 3 quarters · filed 2018-08-08 | $95.15M derived: sum of 4 quarters · filed 2018-08-08 | ||||
| 2017-03-31 | $21.31M 10-Q · filed 2018-05-08 | $57.66M derived: sum of 2 quarters · filed 2018-05-08 | $75.65M derived: sum of 3 quarters · filed 2018-05-08 | $100.38M derived: sum of 4 quarters · filed 2018-05-08 | ||||
| 2016-12-31 | $36.35M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-08 | $54.34M derived: sum of 2 quarters · filed 2018-03-08 | $79.08M derived: sum of 3 quarters · filed 2018-03-08 | $104.45M 10-K · filed 2018-03-08 | ||||
| 2016-09-30 | $17.99M 10-Q · filed 2017-11-07 | $42.73M derived: sum of 2 quarters · filed 2017-11-07 | $68.09M 10-Q · filed 2017-11-07 | $108.06M derived: sum of 4 quarters · filed 2018-03-08 | ||||
| 2016-06-30 | $24.73M 10-Q · filed 2017-08-08 | $50.10M 10-Q · filed 2017-08-08 | $90.07M derived: sum of 3 quarters · filed 2018-03-08 | $115.17M derived: sum of 4 quarters · filed 2018-03-08 | ||||
| 2016-03-31 | $25.37M 10-Q · filed 2017-05-09 | $65.33M derived: sum of 2 quarters · filed 2018-03-08 | $90.43M derived: sum of 3 quarters · filed 2018-03-08 | $116.09M derived: sum of 4 quarters · filed 2018-03-08 | ||||
| 2015-12-31 | $39.96M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-08 | $65.06M derived: sum of 2 quarters · filed 2018-03-08 | $90.72M derived: sum of 3 quarters · filed 2018-03-08 | $114.71M 10-K · filed 2018-03-08 | $114.45M 10-K · filed 2016-02-29 | |||
| 2015-09-30 | $25.10M 10-Q · filed 2016-11-09 | $50.76M derived: sum of 2 quarters · filed 2016-11-09 | $74.75M 10-Q · filed 2016-11-09 | $114.88M derived: sum of 4 quarters · filed 2017-03-03 | ||||
| 2015-06-30 | $25.65M 10-Q · filed 2016-08-09 | $28.56M 10-Q · filed 2015-08-10 | $49.65M 10-Q · filed 2016-08-09 | $55.20M 10-Q · filed 2015-08-10 | $89.78M derived: sum of 3 quarters · filed 2017-03-03 | $117.07M derived: sum of 4 quarters · filed 2017-03-03 | ||
| 2015-03-31 | $23.99M 10-Q · filed 2016-05-09 | $26.65M 10-Q · filed 2015-05-11 | $64.12M derived: sum of 2 quarters · filed 2017-03-03 | $91.42M derived: sum of 3 quarters · filed 2017-03-03 | $118.89M derived: sum of 4 quarters · filed 2017-03-03 | |||
| 2014-12-31 | $40.13M derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-03 | $67.42M derived: sum of 2 quarters · filed 2017-03-03 | $94.90M derived: sum of 3 quarters · filed 2017-03-03 | $116.46M 10-K · filed 2017-03-03 | $115.92M 10-K · filed 2015-02-26 | |||
| 2014-09-30 | $27.29M 10-Q · filed 2015-11-09 | $29.56M 10-Q · filed 2014-11-06 | $54.77M derived: sum of 2 quarters · filed 2015-11-09 | $76.33M 10-Q · filed 2015-11-09 | $82.49M 10-Q · filed 2014-11-06 | $100.85M derived: sum of 4 quarters · filed 2016-02-29 | ||
| 2014-06-30 | $27.48M 10-Q · filed 2015-08-10 | $52.93M 10-Q · filed 2015-08-10 | $73.56M derived: sum of 3 quarters · filed 2016-02-29 | $91.61M derived: sum of 4 quarters · filed 2016-02-29 | ||||
| 2014-03-31 | $25.45M 10-Q · filed 2015-05-11 | $46.08M derived: sum of 2 quarters · filed 2016-02-29 | $64.13M derived: sum of 3 quarters · filed 2016-02-29 | $81.39M derived: sum of 4 quarters · filed 2016-02-29 | ||||
| 2013-12-31 | $20.63M derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-29 | $38.68M derived: sum of 2 quarters · filed 2016-02-29 | $55.94M derived: sum of 3 quarters · filed 2016-02-29 | $70.20M 10-K · filed 2016-02-29 | ||||
| 2013-09-30 | $18.05M 10-Q · filed 2014-11-06 | $35.31M derived: sum of 2 quarters · filed 2014-11-06 | $49.57M 10-Q · filed 2014-11-06 | $64.93M derived: sum of 4 quarters · filed 2015-02-26 | ||||
| 2013-06-30 | $17.27M 10-Q · filed 2014-08-04 | $31.52M 10-Q · filed 2014-08-04 | $46.88M derived: sum of 3 quarters · filed 2015-02-26 | $59.48M derived: sum of 4 quarters · filed 2015-02-26 | ||||
| 2013-03-31 | $14.25M 10-Q · filed 2014-05-12 | $29.62M derived: sum of 2 quarters · filed 2015-02-26 | $42.22M derived: sum of 3 quarters · filed 2015-02-26 | $54.99M derived: sum of 4 quarters · filed 2015-02-26 | ||||
| 2012-12-31 | $15.36M derived: 10-K 12 month − 10-Q 9 month · filed 2015-02-26 | $27.96M derived: sum of 2 quarters · filed 2015-02-26 | $40.73M derived: sum of 3 quarters · filed 2015-02-26 | $51.49M 10-K · filed 2015-02-26 | ||||
| 2012-09-30 | $12.60M 10-Q · filed 2013-11-07 | $25.37M derived: sum of 2 quarters · filed 2013-11-07 | $36.13M 10-Q · filed 2013-11-07 | $48.42M derived: sum of 4 quarters · filed 2014-03-12 | ||||
| 2012-06-30 | $12.77M 10-Q · filed 2013-08-07 | $23.52M 10-Q · filed 2013-08-07 | $35.81M derived: sum of 3 quarters · filed 2014-03-12 | $45.98M derived: sum of 4 quarters · filed 2014-03-12 | ||||
| 2012-03-31 | $10.76M 10-Q · filed 2013-05-09 | $23.05M derived: sum of 2 quarters · filed 2014-03-12 | $33.21M derived: sum of 3 quarters · filed 2014-03-12 | $42.92M derived: sum of 4 quarters · filed 2014-03-12 | ||||
| 2011-12-31 | $12.29M derived: 10-K 12 month − 10-Q 9 month · filed 2014-03-12 | $22.46M derived: sum of 2 quarters · filed 2014-03-12 | $32.17M derived: sum of 3 quarters · filed 2014-03-12 | $40.58M 10-K · filed 2014-03-12 | ||||
| 2011-09-30 | $10.17M 10-Q · filed 2012-11-09 | $19.88M derived: sum of 2 quarters · filed 2012-11-09 | $28.29M 10-Q · filed 2012-11-09 | $37.87M derived: sum of 4 quarters · filed 2013-03-12 | ||||
| 2011-06-30 | $9.71M 10-Q · filed 2012-08-14 | $18.12M 10-Q · filed 2012-08-14 | $27.70M derived: sum of 3 quarters · filed 2013-03-12 | $34.85M derived: sum of 4 quarters · filed 2013-03-12 | ||||
| 2011-03-31 | $8.41M 10-Q · filed 2012-05-15 | $17.99M derived: sum of 2 quarters · filed 2013-03-12 | $25.14M derived: sum of 3 quarters · filed 2013-03-12 | $32.61M derived: sum of 4 quarters · filed 2013-03-12 | ||||
| 2010-12-31 | $9.58M derived: 10-K 12 month − 10-Q 9 month · filed 2013-03-12 | $16.73M derived: sum of 2 quarters · filed 2013-03-12 | $24.20M derived: sum of 3 quarters · filed 2013-03-12 | $30.46M 10-K · filed 2013-03-12 | ||||
| 2010-09-30 | $7.15M 10-Q · filed 2011-11-14 | $14.62M derived: sum of 2 quarters · filed 2011-11-14 | $20.88M 10-Q · filed 2011-11-14 | |||||
| 2010-06-30 | $7.47M 10-Q · filed 2011-08-09 | $13.73M 10-Q · filed 2011-08-09 | ||||||
| 2009-12-31 | $23.60M 10-K · filed 2012-03-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |